在治疗高血压时,脏缩的适应症
Kenichi Katsurada1,2, Kazuomi Kario3
1Division of Cardiovascular Medicine, Department of Internal Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan. katsurada@jichi.ac.jp.
脏缺血 (RDN) 有效地降低了耐药高血压患者的血压. 这种神经调节疗法现在是指导方针推的,并被FDA批准用于特定患者群体.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 神经调节是一种神经调节.
背景情况:
- 抗性高血压影响着大量患者,治疗选择有限.
- 脏缩 (RDN) 是一种新兴的神经调节疗法,针对脏交感神经.
- 最近的试验证明了RDN在降低血压方面的有效性.
研究的目的:
- 审查关于RDN对高血压的安全性和有效性的最新证据.
- 讨论RDN目前的适用情况,包括与抗高血压药物并无使用.
- 突出 RDN 在临床实践中日益增长的作用.
主要方法:
- 审查最近的随机对照试验和临床证据.
- 从RDN程序获得的安全性和有效性数据的分析.
- 欧洲高血压学会和FDA指南的审查.
主要成果:
- RDN在耐药,不受控制和以前未服用过药物的高血压患者中显示出显著的抗高血压作用.
- 欧洲高血压学会的指导方针建议RDN用于抗性高血压.
- 两种RDN系统 (ReCor Paradise,Medtronic Symplicity Spyral) 已获得FDA的批准,用于特定的适应症.
结论:
- RDN是一种安全有效的辅助疗法,用于抵抗性和不受控制的高血压.
- 支持RDN的临床证据越来越多,导致扩大了适应症.
- 预计RDN在高血压管理中的整合将会增加.
更多相关视频
08:21A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
06:30Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
Published on: September 11, 2018
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Antihypertensive Drugs: Potassium-Sparing Diuretics
